Atea Pharmaceuticals Inc <AVIR.OQ> expected to post a loss of 45 cents a share - Earnings Preview

• Atea Pharmaceuticals Inc AVIR.OQ AVIR.O is expected to show no change in quarterly revenue when it reports results on August 7 for the period ending June 30 2025

• ​LSEG's mean analyst estimate for Atea Pharmaceuticals Inc is for a loss of 45 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Atea Pharmaceuticals Inc is $6.00, about 39.3% above its last closing price of $3.64

This summary was machine generated August 1 at 11:55 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)